Found: 8
Select item for more details and to access through your institution.
In Silico SAR Studies of HIV-1 Inhibitors.
- Published in:
- Pharmaceuticals (14248247), 2018, v. 11, n. 3, p. 69, doi. 10.3390/ph11030069
- By:
- Publication type:
- Article
Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment.
- Published in:
- Cell Biochemistry & Biophysics, 2019, v. 77, n. 3, p. 203, doi. 10.1007/s12013-019-00882-5
- By:
- Publication type:
- Article
Monte Carlo Method and GA-MLR-Based QSAR Modeling of NS5A Inhibitors against the Hepatitis C Virus.
- Published in:
- Molecules, 2022, v. 27, n. 9, p. 2729, doi. 10.3390/molecules27092729
- By:
- Publication type:
- Article
Distinguishing the optimal binding mechanism of an E3 ubiquitin ligase: Covalent versus noncovalent inhibition.
- Published in:
- Journal of Cellular Biochemistry, 2019, v. 120, n. 8, p. 12859, doi. 10.1002/jcb.28556
- By:
- Publication type:
- Article
Design, Synthesis, Biological and Computational Assessment of New Thiazolidin‐4‐one Derivatives as Potential Anticancer Agents Through the Apoptosis Pathway.
- Published in:
- ChemistrySelect, 2022, v. 7, n. 21, p. 1, doi. 10.1002/slct.202200165
- By:
- Publication type:
- Article
Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling.
- Published in:
- Molecules, 2019, v. 24, n. 17, p. 3125, doi. 10.3390/molecules24173125
- By:
- Publication type:
- Article
Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
- Published in:
- Protein Journal, 2020, v. 39, n. 2, p. 97, doi. 10.1007/s10930-020-09884-2
- By:
- Publication type:
- Article
Exploring the Structural Mechanism of Covalently Bound E3 Ubiquitin Ligase: Catalytic or Allosteric Inhibition?
- Published in:
- Protein Journal, 2018, v. 37, n. 6, p. 500, doi. 10.1007/s10930-018-9795-5
- By:
- Publication type:
- Article